Aaron Spingarn, MD
Otolaryngology · Hartsdale, NYNPI 1639142078
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $2,794 with a category attached, or 80.5%. Acelrx Pharmaceuticals, Inc. accounts for 81.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $2,311 and has fallen 89.0% since, to $255 in 2025.
Across 26 payments — averaging $107.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acelrx Pharmaceuticals, Inc.$2K
- Medtronic$83
- Pharming Healthcare, Inc.$64
- Aerin Medical Inc.$60
- Biocryst US Sales Co., LLC$54
- Optinose US, Inc.$41
- plus $204 from 9 others
What the payments were for
- Consulting fees$2,25081%
- Food & beverage$54419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acelrx Pharmaceuticals, Inc. | 3 | $2,289 |
| Medtronic | 3 | $83 |
| Pharming Healthcare, Inc. | 3 | $64 |
| Aerin Medical Inc. | 2 | $60 |
| Biocryst US Sales Co., LLC | 3 | $54 |
| Optinose US, Inc. | 2 | $41 |
| Merck | 2 | $36 |
| Integra Lifesciences Corporation | 1 | $29 |
| Lilly USA, LLC | 1 | $26 |
| Neurent Medical Limited | 1 | $23 |
| GSK | 1 | $22 |
| Stryker | 1 | $21 |
| Alk-abello, Inc | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DSUVIA$2,250
How this compares
$2,794 in reported general payments places this provider in the 70th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 133 | $1,563 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 23 | $1,038 |
| Fluocinolone Acetonide Oil | 19 | $802 |
| Ipratropium Bromide | 40 | $686 |
| Amoxicillin | 26 | $97 |
| Azithromycin | 16 | $62 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Hartsdale
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Nitin BhatiaWhite Plains$120K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.